Zai Lab Limited and Innoviva Specialty Therapeutics announced that China’s National Medical Products Administration has approved Zai Lab’s New Drug Application for XACDURO® for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.
